Lung cancer key for Takeda's alisertib after Ph III lymphoma flop
This article was originally published in Scrip
Executive Summary
Takeda's hopes for its first-in-class Aurora kinase inhibitor now rest on Phase II studies in lung cancer after the company pulled the plug on its Phase III trial in a rare form of lymphoma.
You may also be interested in...
Asia Deal Watch: Dong-A Brings In NeuroBo As Partner On Pair Of Cardiometabolic Candidates
Plus deals involving Takeda/Puma, SillaJen/Basilea, Celltrion/Abpro, METiS/Voronoi, Yuhan/AtoGen, Biocytogen/FineImmune and Avance/C3.
Lilly Reacquires Aurora Kinase Inhibitor Via AurKa Buy For $110m
Many Aurora kinase inhibitors have entered development, but while none have had a successful end, Lilly believes the specificity of AurKa's AK-01 will make it a safer drug. The asset fits well into Lilly's oncology strategy, which includes both targeted therapies and immuno-oncology drugs.
Titans Of Pharma 2022: Johnson & Johnson Pays Highest Exec Compensation Again
Infographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.